




Amarin Corporation plc
Investor Relations Department
2 Pembroke House, Upper
Pembroke
Street 28-32
Dublin 2
Ireland

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: AMRN

Last Trade:	3.06
Trade Time:	4:00 PM ET Mar 23, 2018
Change:	-0.06  (-1.923%)
Day Range	3.02 - 3.12
52-Week Range	2.85 - 4.60
Volume	1,654,312

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Mar 21, 2018

[Amarin Announces First Middle East Approval for Vascepa®](#)

Mar 12, 2018

[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein \(hsCRP\)](#)

Mar 12, 2018

[Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs](#)

Mar 5, 2018

[Amarin Announces Closing of Underwriter's Purchase of Additional Shares](#)

Mar 1, 2018

[Amarin Announces Start of Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study](#)

Financials [\[View all \]](#)

[Fourth Quarter Financial Results](#)

Feb 27, 2018

[Annual Report \(10-K\)](#)

Apr 21, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 1, 2017

[Quarterly Report \(10-Q\)](#)

Aug 2, 2017

[Quarterly Report \(10-Q\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)